Advertisement

Novel miRNA PC-5P-12969 in Ischemic Stroke

  • Murali Vijayan
  • Faisal F. Alamri
  • Abdullah Al Shoyaib
  • Vardan T. Karamyan
  • P. Hemachandra ReddyEmail author
Article
  • 104 Downloads

Abstract

Circulating microRNAs (miRNAs) have been used effectively as peripheral biomarkers and mechanistic targets for human diseases such as stroke, Alzheimer’s, and cancer. The purpose of our study is to determine noninvasive, blood-based early detectable biomarkers for ischemic stroke (IS). Based on our previous global miRNA sequencing study, four miRNAs were previously unreported (novel) in IS condition. Among these, miRNA PC-5P-12969 was exclusively expressed in the IS condition; otherwise, it was not expressed in normal condition, and therefore, we focused on miRNA PC-5P-12969 for further studies. In the present study, we investigated novel miRNA PC-5P-12969 for its expression levels using quantitative real-time PCR assay (qRT-PCR) in an in vitro, oxygen, and glucose deprivation/reoxygenation (OGD/R)-treated mouse primary hippocampal neuronal cells (HT22) and in an in vivo using a photothrombotic stroke model. In an in vitro study of stroke-induced HT22 cells, we found a two fold increase of PC-5P-12969 expression levels, in agreement with our original global miRNA study. In the cerebral cortex of photothrombotic stroke mice, we found significantly upregulated levels of PC-5P-12969 in 4 hours and 1 day post-stroke relative to the control mice. However, we did not find any change in the expression of PC-5P-12969 in the cerebellum (unaffected in IS) of both stroke and control mice. Based on findings from this study, together with our earlier original global microRNA study results, we conclude that PC-5P-12969 is a potential candidate of the peripheral marker and also a drug target for IS. This is the first study validating that the miRNA PC-5P-12969, might be a potential biomarker for IS.

Keywords

Ischemic stroke Novel miRNA Biomarker HT22 Infarct volume Photothrombotic stroke model 

Notes

Acknowledgements

We thank Dr. David Schubert (Salk Institute for Biological Studies) for providing the HT22 cells for this study as a gift.

Funding

The research presented in this article was supported by the National Institute of Health grants AG042178, AG47812, and NS105473 and grants from the Garrison Family Foundation and the CH Foundation (PHR).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no competing interests.

References

  1. 1.
    Murali V, Rathika C, Ramgopal S, Padma Malini R, Arun Kumar MJ, Neethi Arasu V et al (2016) Susceptible and protective associations of HLA DRB1*/DQB1* alleles and haplotypes with ischaemic stroke. Int J Immunogenet 43:159–165CrossRefGoogle Scholar
  2. 2.
    Project Principal Investigators WHOMONICA (1988) The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. J Clin Epidemiol 41:105–114CrossRefGoogle Scholar
  3. 3.
    Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R et al American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2017) Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation 135:e146–e603Google Scholar
  4. 4.
    Feigin VL, Norrving B, George MG, Foltz JL, Roth GA, Mensah GA (2016) Prevention of stroke: a strategic global imperative. Nat Rev Neurol 12:501–512CrossRefGoogle Scholar
  5. 5.
    Vijayan M, Reddy PH (2016) Peripheral biomarkers of stroke: focus on circulatory microRNAs. Biochim Biophys Acta 1862:1984–1993CrossRefGoogle Scholar
  6. 6.
    Rotkrua P, Shimada S, Mogushi K, Akiyama Y, Tanaka H, Yuasa Y (2013) Circulating microRNAs as biomarkers for early detection of diffuse-type gastric cancer using a mouse model. Br J Cancer 108:932–940CrossRefGoogle Scholar
  7. 7.
    Chan PH (2001) Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 21:2–14CrossRefGoogle Scholar
  8. 8.
    Vijayan M, Kumar S, Yin X, Zafer D, Chanana V, Cengiz P et al (2018) Identification of novel circulatory microRNA signatures linked to patients with ischemic stroke. Hum Mol Genet 27:2318–2329CrossRefGoogle Scholar
  9. 9.
    Alamri FF, Shoyaib AA, Biggers A, Jayaraman S, Guindon J, Karamyan VT (2018) Applicability of the grip strength and automated von Frey tactile sensitivity tests in the mouse photothrombotic model of stroke. Behav Brain Res 336:250–255CrossRefGoogle Scholar
  10. 10.
    Rashid M, Wangler NJ, Yang L, Shah K, Arumugam TV, Abbruscato TJ et al (2014) Functional up-regulation of endopeptidase neurolysin during post-acute and early recovery phases of experimental stroke in mouse brain. J Neurochem 129:179–189CrossRefGoogle Scholar
  11. 11.
    Kumar P, Dezso Z, MacKenzie C, Oestreicher J, Agoulnik S, Byrne M et al (2013) Circulating miRNA biomarkers for Alzheimer's disease. PLoS One 8:e69807CrossRefGoogle Scholar
  12. 12.
    Wang X, Chen S, Ni J, Cheng J, Jia J, Zhen X (2018) MiRNA-3473b contributes to neuroinflammation following cerebral ischemia. Cell Death Dis 9:11CrossRefGoogle Scholar
  13. 13.
    Saraiva C, Talhada D, Rai A, Ferreira R, Ferreira L, Bernardino L et al (2018) MicroRNA-124-loaded nanoparticles increase survival and neuronal differentiation of neural stem cells in vitro but do not contribute to stroke outcome in vivo. PLoS One 13:e0193609CrossRefGoogle Scholar
  14. 14.
    Sørensen SS, Nygaard AB, Carlsen AL, Heegaard NHH, Bak M, Christensen T (2017) Elevation of brain-enriched miRNAs in cerebrospinal fluid of patients with acute ischemic stroke. Biomark Res 11:5–24Google Scholar
  15. 15.
    Quinlan S, Kenny A, Medina M, Engel T, Jimenez-Mateos EM (2017) MicroRNAs in neurodegenerative diseases. Int Rev Cell Mol Biol 334:309–343CrossRefGoogle Scholar
  16. 16.
    Reddy PH, Tonk S, Kumar S, Vijayan M, Kandimalla R, Kuruva CS, Reddy AP (2017) A critical evaluation of neuroprotective and neurodegenerative microRNAs in Alzheimer's disease. Biochem Biophys Res Commun 483:1156–1165CrossRefGoogle Scholar
  17. 17.
    Nelson PT, Wang WX, Rajeev BW (2008) MicroRNAs (miRNAs) in neurodegenerative diseases. Brain Pathol 18:130–138CrossRefGoogle Scholar
  18. 18.
    Long JM, Ray B, Lahiri DK (2012) MicroRNA-153 physiologically inhibits expression of amyloid-β precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients. J Biol Chem 287:31298–31310CrossRefGoogle Scholar
  19. 19.
    Long JM, Ray B, Lahiri DK (2014) MicroRNA-339-5p down-regulates protein expression of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects. J Biol Chem 289:5184–5198CrossRefGoogle Scholar
  20. 20.
    Kumar S, Vijayan M, Reddy PH (2017) MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer's disease. Hum Mol Genet 26:3808–3822CrossRefGoogle Scholar
  21. 21.
    Satake E, Pezzolesi MG, Md Dom ZI, Smiles AM, Niewczas MA, Krolewski AS (2018) Circulating miRNA Profiles Associated With Hyperglycemia in Patients With Type 1 Diabetes. Diabetes 67:1013–1023CrossRefGoogle Scholar
  22. 22.
    Zhou X, Lu Z, Wang T, Huang Z, Zhu W, Miao Y (2018) Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis. Gene 673:181–193CrossRefGoogle Scholar
  23. 23.
    Lorenzen JM, Thum T (2012) Circulating and urinary microRNAs in kidney disease. Clin J Am Soc Nephrol 7:1528–1533CrossRefGoogle Scholar
  24. 24.
    Fichtlscherer S, Zeiher AM, Dimmeler S (2011) Circulating microRNAs: biomarkers or mediators of cardiovascular diseases? Arterioscler Thromb Vasc Biol 31:2383–2390CrossRefGoogle Scholar
  25. 25.
    Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N, Tanaka WK et al (2009) Plasma microRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 55:1977–1983CrossRefGoogle Scholar
  26. 26.
    Zeng L, Liu J, Wang Y, Wang L, Weng S, Tang Y et al (2011) MicroRNA-210 as a novel blood biomarker in acute cerebral ischemia. Front Biosci (Elite Ed) 1:1265–1272Google Scholar
  27. 27.
    Weng H, Shen C, Hirokawa G, Ji X, Takahashi R, Shimada K et al (2011) Plasma miR- 124 as a biomarker for cerebral infarction. Biomed Res 32:135–141CrossRefGoogle Scholar
  28. 28.
    Gan CS, Wang CW, Tan KS (2012) Circulatory microRNA-145 expression is increased in cerebral ischemia. Genet Mol Res 11:147–152CrossRefGoogle Scholar
  29. 29.
    Sepramaniam S, Tan JR, Tan KS, DeSilva DA, Tavintharan S, Woon FP et al (2014) Circulating microRNAs as biomarkers of acute stroke. Int J Mol Sci 15:1418–1432CrossRefGoogle Scholar
  30. 30.
    Jickling GC, Sharp FR (2011) Blood biomarkers of ischemic stroke. Neurotherapeutics 8:349–360CrossRefGoogle Scholar
  31. 31.
    Khoshnam SE, Winlow W, Farbood Y, Moghaddam HF, Farzaneh M (2017) Emerging Roles of microRNAs in Ischemic Stroke: As Possible Therapeutic Agents. J Stroke 19:166–187CrossRefGoogle Scholar
  32. 32.
    Whiteley W, Tian Y, Jickling GC (2012) Blood biomarkers in stroke: research and clinical practice. Int J Stroke 7:435–439CrossRefGoogle Scholar
  33. 33.
    Wang W, Sun G, Zhang L, Shi L, Zeng Y (2014) Circulating microRNAs as novel potential biomarkers for early diagnosis of acute stroke in humans. J Stroke Cerebrovasc Dis 23:2607–2613CrossRefGoogle Scholar
  34. 34.
    Ziu M, Fletcher L, Rana S, Jimenez DF, Digicaylioglu M (2011) Temporal differences in microRNA expression patterns in astrocytes and neurons after ischemic injury. PLoS One 6:e14724CrossRefGoogle Scholar
  35. 35.
    Long JM, Maloney B, Rogers JT, Lahiri DK (2018) Novel upregulation of amyloid-βprecursor protein (APP) by microRNA-346 via targeting of APP mRNA 5'-untranslated region: Implications in Alzheimer's disease. Mol Psychiatry.  https://doi.org/10.1038/s41380-018-0266-3
  36. 36.
    Koutsis G, Siasos G, Spengos K (2013) The emerging role of microRNA in stroke. Curr Top Med Chem 13:1573–1588CrossRefGoogle Scholar
  37. 37.
    Liu d Z, Jickling GC, Ander BP, Hull H, Zhan X, Cox C et al (2016) Elevating microRNA-122 in blood improves outcomes after temporary middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 36:1374–1383CrossRefGoogle Scholar
  38. 38.
    Fluri F, Schuhmann MK, Kleinschnitz C (2015) Animal models of ischemic stroke and their application in clinical research. Drug Des Devel Ther 9:3445–3454PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Internal MedicineTexas Tech University Health Sciences CenterLubbockUSA
  2. 2.Department of Pharmaceutical Sciences, School of PharmacyTexas Tech University Health Sciences CenterAmarilloUSA
  3. 3.Center for Blood Brain Barrier Research, School of PharmacyTexas Tech University Health Sciences CenterAmarilloUSA
  4. 4.Garrison Institute on AgingTexas Tech University Health Sciences CenterLubbockUSA
  5. 5.Garrison Institute on Aging, South West CampusTexas Tech University Health Sciences CenterLubbockUSA
  6. 6.Cell Biology & Biochemistry DepartmentTexas Tech University Health Sciences CenterLubbockUSA
  7. 7.Pharmacology & Neuroscience DepartmentTexas Tech University Health Sciences CenterLubbockUSA
  8. 8.Neurology DepartmentTexas Tech University Health Sciences CenterLubbockUSA
  9. 9.Speech, Language and Hearing Sciences DepartmentTexas Tech University Health Sciences CenterLubbockUSA
  10. 10.Department of Public Health, Graduate School of Biomedical SciencesLubbockUSA

Personalised recommendations